Epidemiology and etiology of infantile developmental and epileptic encephalopathies in Tasmania by Ware, TL et al.
504 |    Epilepsia Open. 2019;4:504–510.wileyonlinelibrary.com/journal/epi4
Received: 9 April 2019 | Revised: 19 June 2019 | Accepted: 27 June 2019
DOI: 10.1002/epi4.12350  
S H O R T  R E S E A R C H  A R T I C L E
Epidemiology and etiology of infantile developmental and 
epileptic encephalopathies in Tasmania
Tyson L. Ware1  |   Shannon R. Huskins2 |   Bronwyn E. Grinton3 |   Yu‐Chi Liu4,5 |   
Mark F. Bennett3,4,5 |   Michael Harvey3  |   Jacinta McMahon3 |   Danae Andreopoulos‐
Malikotsinas3 |   Melanie Bahlo4,5 |   Katherine B. Howell6,7,8 |   Michael S. Hildebrand3 |   
John A. Damiano3 |   Alexander Rosenfeld3 |   Mark T. Mackay6,7 |   
Simone Mandelstam6,7,8,9,10 |   Richard J. Leventer6,7,8 |   A. Simon Harvey6,7 |    
Jeremy L. Freeman6,7 |   Ingrid E. Scheffer3,6,7,8,10 |   Dean L. Jones2,11 |   Samuel F. Berkovic3
1Department of Paediatrics, Royal Hobart Hospital, Hobart, Tasmania, Australia
2School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
3Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
4The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
5Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
6Royal Children’s Hospital, Melbourne, Victoria, Australia
7Murdoch Children’s Research Institute, Parkville, Victoria, Australia
8Department of Pediatrics, University of Melbourne, Melbourne, Victoria, Australia
9Department of Radiology, University of Melbourne, Melbourne, Victoria, Australia
10Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
11Department of Neurology, Royal Hobart Hospital, Hobart, Tasmania, Australia
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2019 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy.
Correspondence
Tyson L. Ware, Department of Paediatrics, 
Royal Hobart Hospital, Liverpool Street, 
Hobart, 7000 TAS, Australia.
Email: tyson.ware@ths.tas.gov.au; 
emtysware@gmail.com
Funding information
The Epilepsy Society Tasmania and the 
Estate of Kathleen Beulah Grace; National 
Health and Medical Research Council 
(NHMRC) Program, Grant/Award Number: 
1091593; NHMRC Fellowship, Grant/
Award Number: 1104831 and 1102971; 
NHMRC Program, Grant/Award Number: 
1054618
Abstract
We sought to determine incidence, etiologies, and yield of genetic testing in infantile 
onset developmental and epileptic encephalopathies (DEEs) in a population isolate, 
with an intensive multistage approach. Infants born in Tasmania between 2011 and 
2016, with seizure onset <2 years of age, epileptiform EEG, frequent seizures, and 
developmental impairment, were included. Following review of EEG databases, 
medical records, brain MRIs, and other investigations, clinical genetic testing was 
undertaken with subsequent research interrogation of whole exome sequencing 
(WES) in unsolved cases. The incidence of infantile DEEs was 0.44/1000 per year 
(95% confidence interval 0.25 to 0.71), with 16 cases ascertained. The etiology was 
structural in 5/16 cases. A genetic basis was identified in 6 of the remaining 11 cases 
(3 gene panel, 3 WES). In two further cases, WES identified novel variants with 
strong in silico data; however, paternal DNA was not available to support patho-
genicity. The etiology was not determined in 3/16 (19%) cases, with a candidate gene 
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1 |  INTRODUCTION
Infantile developmental and epileptic encephalopathies 
(DEEs) have a range of etiologies including >60 genetic 
causes, and in many patients, the cause remains unknown. The 
infantile DEEs comprise a group of epilepsy syndromes with 
infantile spasms (West syndrome) typically accounting for 
over half the cases.1,2 The incidence of DEEs overall was esti-
mated as 0.27/1000 births in the North London study1 and as 
0.54/1000 per year in our recent Victorian study;2 the differ-
ence was probably related to methodology as each had differ-
ent inclusion criteria and only those with a specific syndrome 
were counted in the North London estimate. Reliable epide-
miological data for the infantile DEEs is required for health 
services planning and will inform the need for genetic testing 
in the diagnosis and management in these severe epilepsies.
Genetic investigations have revolutionized understand-
ing of the causes of DEEs. This knowledge has begun to be 
implemented in the clinic, predominantly using gene panel 
testing, and diagnostic yields are growing as new discoveries 
are made.3 Incorporating whole exome sequencing (WES) 
into the diagnostic protocol of DEEs increases the yield and 
reduces overall costs associated with reaching a diagnosis.2
The Australian island state of Tasmania is a population 
isolate of ~515 000 residents served by only two EEG labora-
tories in its major cities, making it an ideal population for ep-
idemiological studies. More than 94% of Tasmanians have a 
Caucasian ancestry. In this paper, we characterize the pheno-
typic, genetic, and epidemiologic features of infantile DEEs 
in a captured population over a six‐year period, utilizing 
next‐generation molecular investigations in a multistage ap-
proach from clinical gene panels to whole exome sequencing.
2 |  METHODS
Inclusion criteria were infants born in Tasmania between 2011 
and 2016, with onset of seizures <2 years of age, epileptiform 
features on EEG, frequent seizures defined as >daily for a 
week or >weekly for a month, and evidence of developmental 
delay, plateauing, or regression. Infants with infantile spasms 
were included irrespective of seizure frequency. Patients with 
acute symptomatic seizures such as those associated with hy-
poxic‐ischemic encephalopathy were excluded. Patients were 
identified through contact with all Tasmanian pediatricians 
and pediatric neurologists and comprehensive review of EEG 
reports. EEG reports were reviewed from 2009 to 2016 to 
ensure full inclusion. All EEGs reported abnormal were re-
viewed by two neurologists (TLW and DLJ) to confirm the 
presence of definitive epileptiform discharges.
The ascertainment process is shown in Figure S1. We 
screened >1200 EEG records and identified 89 patients with 
epileptiform features. Seventy‐three cases were excluded; 40 
due to age or date of onset; 24 had a mild or self‐limited epi-
lepsy syndrome; 4 had normal developmental outcome; and 5 
had acute symptomatic seizures (four with neonatal hypoxic‐
ischemic encephalopathy and one with traumatic brain injury).
Clinical details obtained included developmental history, 
seizure semiology, and comorbidities from interview, review 
of medical records, and a validated seizure questionnaire.4 
EEG findings, neuroimaging, and metabolic investigations 
were reviewed. Specific epilepsy syndromes were diagnosed 
where possible.
Research WES was conducted using Agilent SureSelect XT 
Human All Exon + UTR v5 (75 Mb) kit and 100 bp paired‐
end sequencing on the HiSeq 2500 System. Trio WES analysis 
including both parents was performed to allow segregation of 
variants, where possible. WES read mapping, alignment pro-
cessing, and variant calling were performed using GATK best 
practices.5 Initially, a panel of 423 candidate genes was inter-
rogated from the WES for single nucleotide variants and, if this 
was negative, exome‐wide analysis was performed. Ultrarare 
variants predicted to result in functional changes and segregat-
ing with affected status were validated by Sanger sequencing. 
Plausible connections to epilepsy or neurodevelopmental con-
ditions were investigated by review of the literature and per-
forming functional studies (reported separately;6 Berecki et al, 
in submission). Pathogenicity of variants was assessed accord-
ing to ACMG criteria.7 Data from unsolved cases were regu-
larly re‐reviewed at 6‐ to 12‐month intervals. Ethical approval 
was obtained from the Human Research and Ethics Committee 
(Tasmania) Network (Reference H0013627).
3 |  RESULTS
Sixteen patients met the criteria for incident infantile 
DEEs in the six‐year period. All were of Anglo‐Australian 
identified in one of these. Pursuing clinical imaging and genetic testing followed by 
WES at an intensive research level can give a high diagnostic yield in the infantile 
DEEs, providing a solid base for prognostic and genetic counseling.
K E Y W O R D S
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background. All patients were identified from review of EEG 
records or by pediatric neurologists servicing Tasmania. 
Correspondence with pediatricians around the state did not 
identify any additional patients.
Of the 16 patients, 5 were male. Clinical and molec-
ular findings are summarized in Table 1. Twelve had ab-
normal development prior to seizure onset or as newborn 
infants. Median seizure onset was 6 months (range 3 days to 
20 months). Six patients had West syndrome with infantile 
spasms.
There were 36 408 births in Tasmania in 2011‐2016 with 
net migration in this period being negligible.8 The incidence 
of infantile DEEs and infantile spasms in Tasmania was 
0.44/1000 (95% confidence interval 0.25 to 0.71) per year 
and 0.17/1000 (95% confidence interval 0.06 to 0.36) per 
year, respectively.
At ascertainment, five infants had an established etiology 
based on history and neuroimaging (Table 1). Cases 1 and 2 
had lissencephaly including one with a causative copy num-
ber variant (17p13.3 Miller‐Dieker microdeletion) and the 
second with a mosaic microduplication at 17p regarded as 
likely pathogenic. One patient had focal cortical dysplasia, 
and one had clinically confirmed tuberous sclerosis (genetic 
testing not performed). Case 5 had extensive unilateral cystic 
encephalomalacia, consistent with a large perinatal anterior 
circulation infarct. As this patient presented with infantile 
spasms, she met our inclusion criteria despite the acquired 
cause. There were no metabolic etiologies identified in our 
cohort.
The etiology was unknown at ascertainment in the re-
maining 11 patients (cases 6‐16); however, three subse-
quently had positive clinical genetic testing. Two had de 
novo KCNQ2 variants, and one had an intronic change 
in ARX resulting in retention of intron 4 and predicted 
early termination of the ARX protein;6 the variant segre-
gated with autism spectrum disorder in his mildly affected 
mother and brother.
Three patients had pathogenic or likely pathogenic 
variants identified on research genetic testing in DHDDS, 
GABRB2 (reported in9), and CACNA1G. For case 12 with 
a variant in CACNA1G, in vitro electrophysiological evalu-
ation showed a pathogenic gain of function (Berecki et al, 
in submission). Cases 9 and 13, with heterozygous variants 
in SCN8A and SNAP25, respectively, were regarded as likely 
solved, as their clinical patterns were consistent with the lit-
erature, and there was strong in silico data. However, as both 
were novel variants and paternal DNA was unavailable for 
segregation, the ACMG classification for these two cases re-
mained “uncertain significance.”
Three cases were regarded as currently unsolved. Case 
14 had compound heterozygous variants in FAT1; segre-
gation analysis confirmed one variant was inherited from 
each parent. Both variants were regarded as damaging 
on in silico analysis, but the gene is not established as a 
DEE gene, so the variants were regarded as of uncertain 
significance.
Etiology for two patients remains unknown despite de-
tailed review of exome‐wide variants. For one, trio data are 
available, but for the other parental DNA was not available. 
Further clinical descriptions and variant details are given in 
the supporting information.
4 |  DISCUSSION
The incidence of the infantile DEEs in Tasmania (0.44/1000 
per year) is consistent with estimates from North London, 
UK, and Victoria, Australia.1,2 Our incidence of infan-
tile spasms (0.17/1000 per year) was at the lower end of 
previous estimates, which ranged from 0.2‐0.45/1000 per 
year).1,2,10,11 The Victorian study also included patients with 
acquired brain injuries (12% of the cohort), whereas these 
patients were excluded from our study with the exception 
of one who had infantile spasms (an automatic inclusion).
The etiology of the epilepsy was definitively identified 
in 11 of our 16 patients (69%). Five had a major structural 
abnormality. Genetics was important in this group with a de-
fined genetic etiology in the two lissencephaly cases and a 
presumed but unstudied genetic abnormality in the tuberous 
sclerosis case.
Of the nonstructural cases, 6/11 had a definite genetic 
etiology. If we include cases 9 and 13, where the identi-
fied genes were highly plausible in terms of pathogenicity 
(SCN8A, SNAP25), but the absence of proof of a de novo 
etiology precluded strict ACMG classification as pathogenic, 
then the diagnostic success rate for the whole cohort climbs 
to 81% (Figure 1). Although our sample size was small, this 
high success rate in identifying the etiology can be attributed 
in part to the intensive scrutiny of WES data. This included 
trio testing where possible, consideration of various modes 
of inheritance including mosaicism and repeated interroga-
tion incorporating newly published data into our analysis 
after standard clinical testing. Our rigorous testing identified 
genetic etiologies in two cases that were negative on initial 
exome‐wide analysis, as has also been shown to be valuable 
in other studies of unsolved DEE cases.12,13
The reported diagnostic yield of genetic testing in infan-
tile DEEs depends on the methods used, the inclusion criteria 
of the sample population, and whether “solved” patients with 
prior testing have been excluded. Recent studies generally 
find that 25%‐50% of cases are solved,2,14‒17 although one 
study of a selected group of 14 cases studied by trio whole 
genome sequencing claimed diagnostic findings in all.18 Our 
findings provide a “real‐world” estimate reflecting that pa-
rental samples are not always obtainable from an epidemio-
logically ascertained cohort.
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Strengths of our study are that the cohort was ascertained 
by comprehensive review of all EEG recordings performed in 
Tasmania from 2009 to 2016 and contact with all pediatricians 
and neurologists caring for children. The data are thus likely 
to be complete, which is supported by our incidence estimates 
being in broad agreement with others. It is possible, but unlikely, 
T A B L E  1  Clinical and etiology findings in epidemiological cohort of infantile DEEs
Subject number/Gender 
age at last review
Onset age of 
seizures
Syndrome Clinical details Etiology
1/ F
2 y4 mo
8 mo
West syndrome
Epileptic spasms
Profound GDD
EEG: Hypsarrhythmia
MRI: Moderate lissencephaly, gradient: poste-
rior more severe than anterior
Lissencephaly
Miller‐Dieker 17p13.3 microdeletion
2/ M
6 y1 mo
7 mo
West syndrome
Spasms, focal motor seizures
Profound GDD
EEG: Hypsarrhythmia
MRI: Moderate lissencephaly, gradient: 
posterior more severe than anterior, pontine 
hypoplasia
Lissencephaly
17p mosaic microduplication
3/ M
2 y6 mo
20 mo
DEE
Unifocal seizures
Regression with seizures. Surgery curative. 
Mild language delay
EEG: Left frontotemporal IEDs
MRI: Segmental focal cortical dysplasia, sub-
ependymal nodules
Focal cortical dysplasia
Genetic testing not done
4/ F
4 y4 mo
2 wk
DEE
Focal tonic, FIAS
Plateau with seizures. Mild language delay.
EEG: Multifocal IEDs.
MRI: Multifocal tubers.
Tuberous sclerosis complex
Genetic testing not done
5/ F
4 y1 mo
5 mo
West syndrome
Spasms, Focal motor seizures
Hemiplegia, regression with spasms
EEG: Hypsarrhythmia; unifocal centro‐tempo-
ral spike IEDs
MRI: Antenatal venous infarction with multi-
cystic encephalomalacia
Antenatal clastic vascular
Genetic testing not done
6/ F
2 y3 mo
3 d
EIMFS
Focal seizures, migrating focal seizures
Mild GDD
EEG: Ictal rhythms migrating between hemi-
spheres; 6 mo & 13 mo normal
MRI: Normal
KCNQ2
c.637C>T p.Arg213Trpa
de novo
Pathogenicb
7/ F
2 y1 mo
2 mo
West syndrome
Focal tonic seizures, spasms, multifocal 
myoclonia
Acquired microcephaly, dyskinesia, profound 
GDD
EEG: Hypsarrhythmia; multifocal discharges
MRI: Acquired moderate cerebral atrophy
KCNQ2
c.593G>A p.Arg198Glna
de novo
Pathogenicb
8/ M
19 mo
4 wk
DEE
Tonic‐clonic seizures, focal tonic seizures
Severe GDD
EEG: Bilateral occipital IEDs
MRI: Hypoplastic corpus callosum
ARX
c.1449‐1 G>C p.Leu484*c
Pathogenicb
9/ F
5 y4 mo
6 mo
DEE
Tonic‐clonic seizures, FBTC
Language delay
EEG: 11 mo‐Ictal rhythm midline to frontocen-
tral regions; 2 y1 mo‐GSW, PSW
MRI: Normal
SCN8A
c. 5009T>G p.Met1670Argc
Uncertain significanceb
(de novo status unproven)
(Continues)
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that patients with infantile DEEs may have been missed if they 
had not come to the attention of the mainstream medical profes-
sion or are cared for solely by a general practitioner, especially 
in the remote areas of Tasmania. Also, our combined clinical 
and research genetic approach resulted in a very high yield.
A weakness of our study is the small sample size; thus, 
while our global estimates are robust, we cannot provide 
estimates of the frequency of individual syndromes or 
genes. Indeed, based on established estimates of the in-
cidence of Dravet syndrome, one to two cases of Dravet 
syndrome might have been expected in our cohort.19 The 
lack of Dravet cases in our cohort is most likely because 
they will not have satisfied inclusion criteria. It is likely 
that their EEG is normal in the first 2 years of life, seizures 
Subject number/Gender 
age at last review
Onset age of 
seizures
Syndrome Clinical details Etiology
10/ F
5 y10 mo
6 mo
DEE
Absence with eyelid myoclonia, absence, eye-
lid myoclonia, myoclonic jerks, tonic‐clonic 
seizures, NCSE
Profound GDD, visual impairment
EEG: Marked photosensitivity, 3‐4Hz GSW, 
PSW, myoclonic‐atonic seizure
MRI: Normal
DHDDS
c.632G>A p.Arg211Glna
de novo
Pathogenicb
11/ M deceased 17 d 5 d
EME
Myoclonic jerks
Decreased activity, poor feeding, jitteriness
EEG: Burst suppression
MRI: Normal
GABRB2
c.851C>A p.Thr284Lysc
de novo
Likely pathogenicb
12/ F
8 y3 mo
7 mo
DEE
Febrile seizures, vibratory tonic seizures, tonic‐
clonic seizures, absence
Profound GDD, hypotonia, truncal ataxia, 
ambulating with walker at 4 y
EEG: GSW, multifocal discharges, PSW
MRI: Normal, no cerebellar atrophy
CACNA1G
c.2727G>C p.Leu909Phec
Likely pathogenic (gain of function in vitro 
[unpublished]; de novo status unproven)b
13/ F
4 y7 mo
5 mo
West syndrome
Spasms
Remission at 8 mo, severe ID and GDD, sei-
zure free without medication
EEG: Hypsarrhythmia
MRI: Normal
SNAP25
c. 526C>T p.Arg176Cysc
Uncertain significanceb
(de novo status unproven)
14/ F
4 y10 mo
13 mo
DEE
Myoclonic jerks; Focal motor seizures at 2 y
Hypotonia, delayed visual maturation, severe 
ID and GDD
EEG: Multifocal discharges, normal at 23 mo
MRI: Normal
Unknown
Candidate gene: FAT1
c.8626G>C p.Asp2876Hisc
c.7655A>G p.Glu2552Glyc
Uncertain significanceb
15/ M
4 y6 mo
9 mo
West syndrome
Spasms
Developmental plateau with spasms
EEG: Hypsarrhythmia
MRI: Normal
Unknown
16/ F
6 y9 mo
10 mo
DEE
Focal tonic seizures, tonic‐clonic seizures, 
FIAS
Specific learning difficulties
EEG: 15 mo‐normal; 21 mo‐occipital ictal 
rhythm; 22 mo‐occipital IEDs; 4 y‐normal
MRI: Normal
Unknown
Abbreviations: BS, burst suppression; DEE, developmental and epileptic encephalopathy; EIMFS, epilepsy of infancy with migrating focal seizures; EME, early 
myoclonic encephalopathy; FBTC, focal to bilateral tonic‐clonic seizure; FIAS, focal impaired awareness seizure; GDD, global developmental delay; GSW, general-
ized spike‐wave; ID, intellectual disability; IEDs, interictal epileptiform discharges; MFDs, multifocal discharges; NCSE, nonconvulsive status epilepticus; PSW, 
polyspike‐wave.
apreviously published variant. 
bACMG classification. 
cNovel variant. 
T A B L E  1  (Continued)
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may be infrequent in infancy and always associated with 
fever (therefore diagnosed as febrile seizures), and devel-
opmental decline may not yet be apparent.20 Whole genome 
sequencing studies may reveal pathogenic variants not 
identified by WES.
Our hypothesis‐free, intensive, multistage approach to 
genetic testing identified pathogenic or likely pathogenic 
variants in a number of DEE genes. Our findings directly 
informed diagnosis, treatment, and prognostic planning for 
these infants and enabled accurate reproductive counseling 
for their parents.
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